Medical management of diabetic retinopathy

Diabet Med. 2004 Jul;21(7):666-72. doi: 10.1111/j.1464-5491.2004.01208.x.

Abstract

Although current treatment and prevention of diabetic retinopathy with laser photocoagulation, and tight metabolic and blood pressure control has reduced the risk of visual loss, there is still a need for additional therapies. A literature review on medical therapies for diabetic retinopathy has been performed, and the following classes of drugs are discussed: blockers of the renin-angiotensin system, protein kinase C-beta inhibitors, glitazones, somatostatin analogues, lipid-lowering drugs and anti-inflammatory drugs. There is experimental and clinical data suggesting beneficial effect from several classes of drugs on diabetic retinopathy, and results from large clinical trials are awaited within the next 3-4 years.

Publication types

  • Review

MeSH terms

  • Diabetic Retinopathy / drug therapy*
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C beta
  • Renin-Angiotensin System / drug effects
  • Somatostatin / analogs & derivatives
  • Thiazolidinediones / therapeutic use

Substances

  • Enzyme Inhibitors
  • Hypolipidemic Agents
  • Thiazolidinediones
  • Somatostatin
  • 2,4-thiazolidinedione
  • Protein Kinase C
  • Protein Kinase C beta